Final 5-year analysis of a phase 2 RCT in 207 patients with HR+/HER2+ early breast cancer: estimated overall survival was 100% with neoadjuvant endocrine therapy plus trastuzumab/pertuzumab vs 97.9% with paclitaxel plus trastuzumab/pertuzumab.
RCTn = 207
Gluz et al. Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer